Cat. No. 1227
Chemical Name: 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4
Biological ActivityProtein kinase inhibitor. Suppresses tumor-promoting effects of TPA and exhibits antiproliferative activity in human breast cancer cells (IC50 values are 59.44 and 31.15 μM at 24 and 72 hrs respectively). Activates both the intrinsic and extrinsic apoptotic pathways and displays anti-inflammatory, hypotensive, antispasmodic and antioxidant properties in vivo.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Sato et al (1994) Apigenin induces morphological differentiation and G2-M arrest in rat neuronal cells. Biochem.Biophys.Res.Commun. 204 578. PMID: 7980517.
Kuo and Yang (1995) Reversion of v-H-ras-transformed NIH3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem.Biophys.Res.Commun. 212 767. PMID: 7626110.
Lin et al (1997) Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J.Cell.Biochem.Suppl. 28-29 39. PMID: 9589348.
Choi et al (2009) Apigen induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells. J.Clin.Biochem.Nutr. 44 260. PMID: 19430615.
Jin et al (2009) Apigenin protects endothelium-dependent relaxation of rat aorta against oxidative stress. Eur.J.Pharmacol. 616 200. PMID: 19549516.
If you know of a relevant citation for this product please let us know.
Keywords: Apigenin, supplier, Protein, kinase, inhibitors, Kinases, Broad, Spectrum
Find multiple products by catalog number
New Products in this Area
CaM kinase II inhibitor; water soluble version of KN-93 (Cat. No. 1278).Bryostatin 3
Potent protein kinase C activatorGKA 50
Glucokinase activatorMRT 67307 dihydrochloride
Salt inducible kinase (SIK) inhibitorLDN 209929 dihydrochloride
Potent and selective haspin kinase inhibitorRKI 1447 dihydrochloride
Potent and selective ROCK inhibitor; antitumorLIMKi 3
Potent LIM kinase inhibitor; antitumorFRAX 486
Potent p21-activated kinase (PAK) inhibitor; brain penetrant and orally bioavailableBIX 02189
Selective MEK5 and ERK5 inhibitorTC Mps1 12
Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor; orally activeGSK 2606414
Potent and selective PERK inhibitor; orally bioavailableAZ 20
Potent and selective ATR kinase inhibitor; antitumorAZD 7762 hydrochloride
Potent and selective ATP-competitive inhibitor of Chk1 and Chk2PHT 427
Dual Akt and PDK1 inhibitor; antitumorML 786 dihydrochloride
Potent Raf kinase inhibitor; orally bioavailableSenexin A
Cyclin-dependent kinase 8 (cdk8) inhibitorXL 388
Potent and selective mTOR inhibitor; antitumor
November 15 - 19, 2014
Washington D.C., USA